Apnimed, Inc.

Apnimed, Inc. (APMD) priced its initial public offering on Jul 31, 2026 at $16.00 per share, within its $14.00–$16.00 range, raising $192M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $637.2M. BofA Securities was lead-left underwriter, joined by Evercore ISI and Cantor. Goodwin Procter advised the company and Cleary Gottlieb advised the underwriters.

Apnimed, Inc. is a late-stage clinical pharmaceutical company developing oral therapies for sleep-related breathing diseases. Its sole clinical candidate, AD109, is a fixed-dose combination being developed to treat obstructive sleep apnea.

Status

IPO

Ticker

APMD

Exchange

Nasdaq Global Select

Priced

Jul 31, 2026

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$192M

Market cap at IPO price

$637.2M

First filed

Jul 10, 2026

Underwriters

BofA Securities, Evercore ISI and Cantor

Company counsel

Goodwin Procter

Underwriters' counsel

Cleary Gottlieb

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.